Product Information

TOBRAMYCIN-DEXAMETH OPHTH SUSP is a generic product labeled by Sandoz Inc., priced at $4.2381 per ML under NDC 61314064710. Its NADAC has been published 678 times since Nov 28, 2013.

FDA first approved this application on Aug 18, 1988. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TOBRAMYCIN-DEXAMETH OPHTH SUSP

Tobramycin and Dexamethasone
$4.2381per ML

Strength

1; 3 mg/mL; mg/mL

Manufacturer

Sandoz Inc.

NDC

61314064710

Classification

Generic

Dosage Form

SUSPENSION/ DROPS

Route

OPHTHALMIC

Effective Date

11/18/2026

Active Ingredients

DEXAMETHASONE; TOBRAMYCIN

Approval Type

Authorized Generic (NDA)

FDA Application

NDA050592

FDA Approved

8/18/1988

TE Code

AB

On Market Since

1/2/2009

Pharmacological Classes

Aminoglycoside Antibacterial
Aminoglycosides
Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has been published 678 times since Nov 28, 2013, and over the history we have for it it has declined 76.4%. The table below summarizes its recorded NADAC range and movement.

Current price$4.2381 per ML
All-time high$18.2963 (Jan 15, 2014)
All-time low$2.8218 (Nov 20, 2024)
52-week high$4.9644
52-week low$4.1561
Median price$13.5570
Average price$11.5933
Largest weekly change+67.2% (Aug 23, 2023)
Weeks tracked678
Tracking sinceNov 28, 2013

Price History

1W

-1.1%

1M

+1.4%

3M

-2.4%

6M

-14.6%

1Y

-12.8%

3Y

+6.1%

5Y

-72.4%

All

-76.4%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TOBRAMYCIN-DEXAMETH OPHTH SUSP?

The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN-DEXAMETH OPHTH SUSP, manufactured by Sandoz Inc., is $4.2381 per ML (NDC 61314064710), effective Nov 18, 2026.

How has the price of TOBRAMYCIN-DEXAMETH OPHTH SUSP changed over time?

Over the history we have for it, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has declined 76.4%. It has been tracked across 678 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Since Nov 28, 2013, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has ranged from a low of $2.8218 (Nov 20, 2024) to a high of $18.2963 (Jan 15, 2014), with a median of $13.5570 per ML.

Are there cheaper alternatives to TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOBRAMYCIN-DEXAMETH OPHTH SUSP, is $3.6789 per ML — about 13% below TOBRAMYCIN-DEXAMETH OPHTH SUSP.

Who manufactures TOBRAMYCIN-DEXAMETH OPHTH SUSP?

TOBRAMYCIN-DEXAMETH OPHTH SUSP (NDC 61314064710) is labeled by Sandoz Inc., and CMS classifies it as a generic product.